About EDC: Michael Minor says EDC has a significant place in global data management strategies. Year In Preview From the clinic to the market to the boardroom, a plethora of factors are expected to change the healthcare landscape in the coming year and beyond. More than 135 distinguished industry executives, representing all of the major sectors of the life-sciences industry, provide their insights on the hot topics and discuss how these market shapers are expected to influence business, strategies, and the bottom line in 2006. In the Clinic Stakeholders involved with drug development and the clinical-trial process are rising to the challenges to improve efficiencies, reduce costs, and accelerate time lines. Research and Development Biopharmaceuticals Nanotechnology Clinical Operations CROs and Outsourcing EDC Drug Safety/Patient Safety Regulatory On the Market Compounds have a one in nine chance of making it through development, according to statistics, but even after reaching the market, each compound faces a whole new set of hurdles: physician adoption, reimbursement, and exposure to supply chain vulnerabilities. Advertising/Consumer Promotion E-Marketing Market Research Salesforces E-Detailing Medical Education Medicare Outcomes Data/Phase IV The Supply Chain In the boardroom From defining and redefining organizational business models for big pharma, biotech, and emerging pharma to tactical decisions related to developing generic defense strategies to improving communications and corporate reputation plans to grappling with technology issues, today’s pharmaceutical leaders are relying on business-savvy solutions. Business and Organizational Models Biotechnology Business Emerging Company Strategies Generic Defense Strategies Communications Stratagies Industry Value and Public Relations Technology In Every Issue Letter from the Editor About E-Marketing: Mark Perlotto says Internet-based market research facilitates a broader geographic reach. About Generics: Mark Goldstone says the pace of expirations is increasing, and generics companies can smell blood. special issue 2006 – Year in Preview About Advertising/Consumer Promotion: Jon Hess says publication strategies are essential to success. About Public Trust: Dr. Cameron Durrant says transparency and evidence are necessary to regain the public’s trust. December 2005 PharmaVOICE Contents
